Clinical Trials Logo

Clinical Trial Summary

This study was attempted to investigate the efficiency of NK cells immunotherapy on non-small cell lung cancer with and without EGFR mutation, and evaluated response rate (RR) and the progression-free survival (PFS).


Clinical Trial Description

Investigators will enrolle 100 patients who met the enrollment criteria. 50 patients were clinically confirmed EGFR mutation positive. They were divided into two groups (group A and group C according to if accepted NK therapy) in accordance with the principles of randomized. The rest 50 patients which were EGFR mutation negative were also divided into two groups (group B and group D) in accordance with the principles of randomized to be paired respectively with group A and group C. Comparison of lymphocyte number, serum tumor related biomarkers, circulating Tumor Cell (CTC), KPS and survival curves was carried out before after NK cell immunotherapy. The safety and short-term effects were evaluated followed by the median PDA, response rate assessment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03662477
Study type Interventional
Source Shenzhen Fifth People's Hospital
Contact TAO LIU, PHD
Phone 13682481027
Email 13682481027@163.com
Status Recruiting
Phase Early Phase 1
Start date January 1, 2018
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT04377113 - Cellular Immunity and Renal Cell Cancer
Not yet recruiting NCT03948828 - Clinical Study of NK Cells in the Treatment of Severe Endometriosis Phase 1
Not yet recruiting NCT03554889 - Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells Phase 1